Hybrid Capture‐Based Genomic Profiling Identifies BRAF V600 and Non‐V600 Alterations in Melanoma Samples Negative by Prior Testing

BACKGROUND. BRAF and MEK inhibitors are approved for BRAF V600‐mutated advanced melanoma, with response rates of up to 70%. Responses to targeted therapies have also been observed for diverse non‐V600 BRAF alterations. Thus, sensitive, accurate, and broad detection of BRAF alterations is critical to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Boussemart, Lise, Nelson, Annie, Wong, Michael, Ross, Jeffrey S., Sosman, Jeffrey, Mehnert, Janice, Daniels, Gregory, Kendra, Kari, Ali, Siraj Mahamed, Miller, Vincent A., Schrock, Alexa B.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Melanoma and Cutaneous Malignancies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516121/
https://ncbi.nlm.nih.gov/pubmed/30683711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0271
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados